Similar articles

Abstract: intravascular large B-cell lymphoma (IVLBCL), a rare subtype of non-Hodgkin lymphoma, is classified as an independent subtype of extranodal diffuse large B-cell lymphoma (DLBCL) in the 2008 World Health Organization (WHO) Classification (Turner et al., 2010). The 5th edition of the World Health Organization (WHO 2022) classification of hematolymphoid tumors retains this subtype (Alaggio et al., 2022). IVLBCL, which is characterized by neoplastic lymphocyte proliferation within the lumen of small blood vessels, tends to invade organs, such as the nervous system, skin, bone marrow (BM), and lung (D'Angelo et al., 2019; Satoh et al., 2019; V�squez et al., 2019; Fukami et al., 2020).

血管内大B细胞淋巴瘤患者未被满足的需求：3例报告及文献复习

[1]AlaggioR,AmadorC,AnagnostopoulosI,et al.,2022.The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia,36(7):1720-1748.

[2]BrunetV,MarouanS,RoutyJP,et al.,2017.Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: a retrospective study of 29 case reports.Medicine (Baltimore),96(5):e5985.

[3]ChenJM,LuoB,LuoXX,et al.,2021.Clinical subtypes, diagnosis, treatment and prognosis of intravascular large B-cell lymphoma in China.Chin J Oncol Prev Treat,13(3):288-29(in Chinese).

[4]D'AngeloCR,KuK,GulliverJ,et al.,2019.Intravascular large B-cell lymphoma presenting with altered mental status: a case report.World J Clin Oncol,10(12):402-408.

[5]DavisJW,AuerbachA,CrothersBA,et al.,2022.Intravascular large B-cell lymphoma.Arch Pathol Lab Med,146(9):1160-1167.

[6]FerreriAJM,CampoE,AmbrosettiA,et al.,2004a.Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.Ann Oncol,15(8):1215-1221.

[7]FerreriAJM,CampoE,SeymourJF,et al.,2004b.Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’.Br J Haematol,127(2):173-183.

[8]FerreriAJM,DogniniGP,BaireyO,et al.,2008.The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma.Br J Haematol,143(2):253-257.

[9]FromowitzFB,ViolaMV,ChaoS,et al.,1987.ras p21 expression in the progression of breast cancer.Hum Pathol,18(12):1268-1275.

[10]FukamiY,KoikeH,IijimaM,et al.,2020.Demyelinating neuropathy due to intravascular large B-cell lymphoma.Intern Med,59(3):435-438.

[11]GeerM,RobertsE,ShangoM,et al.,2019.Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.Br J Haematol,186(2):255-262.

[12]Gonzalez-FarreB,Ramis-ZaldivarJE,de AntaNC,et al.,2023.Intravascular large B-cell lymphoma genomic profile is characterized by alterations in genes regulating NF-κB and immune checkpoints.Am J Surg Pathol,47(2):202-211.

[13]GuptaGK,JaffeES,PittalugaS,2019.A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.Histopathology,75(2):282-286.

[14]KandaM,SuzumiyaJ,OhshimaK,et al.,2001.Analysis of the immunoglobulin heavy chain gene variable region of intravascular large B-cell lymphoma.Virchows Arch,439(4):540-546.

[15]KatoK,MoriT,KimSW,et al.,2019.Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation.Bone Marrow Transplant,54(9):1515-1517.

[16]KlairmontMM,ChengJJ,MartinMG,et al.,2018.Recurrent cytogenetic abnormalities in intravascular large B-cell lymphoma.Am J Clin Pathol,150(1):18-26.

[17]LiuZY,ZhangYL,ZhuYC,et al.,2020.Prognosis of intravascular large B cell lymphoma (IVLBCL): analysis of 182 patients from global case series.Cancer Manag Res,12:10531-10540.

[18]LuoCC,YuTT,YoungKH,et al.,2022.HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.J Zhejiang Univ-Sci B (Biomed & Biotechnol),23(8):666-681.

[19]Lymphoid Disease Group,Chinese Society of Hematology,Chinese Medical Association,et al.,2023.Chinese expert consensus on the diagnosis and management of intravascular large B cell lymphoma (2023).Chin J Hematol,44(3):177-181(in Chinese).

[20]MahadevanD,SpierC,Della CroceK,et al.,2005.Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.Mol Cancer Ther,4(12):1867-1879.

[21]MatsueK,AbeY,NaritaK,et al.,2019.Diagnosis of intravascular large B cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years.Br J Haematol,187(3):328-336.

[22]MeissnerJ,FinelH,DietrichS,et al.,2017.Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.Bone Marrow Transplant,52(4):650-652.

[23]MuftahS,XuZD,el GaddafiW,et al.,2012.Synchronous intravascular large B-cell lymphoma within meningioma.Neuropathology,32(1):77-81.

[24]MuraseT,NakamuraS,KawauchiK,et al.,2000.An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome.Br J Haematol,111(3):826-834.

[25]MuraseT,YamaguchiM,SuzukiR,et al.,2007.Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.Blood,109(2):478-485.

[26]PolettoS,NovoM,ParuzzoL,et al.,2022.Treatment strategies for patients with diffuse large B-cell lymphoma.Cancer Treat Rev,110:102443.

[27]PonzoniM,FerreriAJM,CampoE,et al.,2007.Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.J Clin Oncol,25(21):3168-3173.

[28]PonzoniM,CampoE,NakamuraS,2018.Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks.Blood,132(15):1561-1567.

[29]QiuLQ,WangSA,VegaF,et al.,2022.From the archives of MD Anderson Cancer Center: intravascular large B-cell lymphoma with numerous circulating lymphoma cells.Ann Diagn Pathol,58:151934.

[30]RajyaguruDJ,BhaskarC,BorgertAJ,et al.,2017.Intravascular large B-cell lymphoma in the United States (US): a population-based study using surveillance, epidemiology, and end results program and national cancer database.Leuk Lymphoma,58(9):2080-2088.

[31]SakakibaraA,InagakiY,ImaokaE,et al.,2018.Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.J Clin Exp Hematop,58(1):32-35.

[32]SatohT,AraiE,KayanoH,et al.,2019.Pulmonary intravascular large B-cell lymphoma accompanying synchronous primary pulmonary adenocarcinoma and benign interstitial lesions.J Clin Exp Hematop,59(3):140-144.

[33]SchmitzR,WrightGW,HuangDW,et al.,2018.Genetics and pathogenesis of diffuse large B-Cell lymphoma.N Engl J Med,378(15):1396-1407.

[34]ShimadaK,MatsueK,YamamotoK,et al.,2008.Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.J Clin Oncol,26(19):3189-3195.

[35]ShimadaK,MuraseT,MatsueK,et al.,2010.Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.Cancer Sci,101(6):1480-1486.

[36]ShimadaK,YamaguchiM,AtsutaY,et al.,2020.Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.Lancet Oncol,21(4):593-602.

[37]ShimadaK,YoshidaK,SuzukiY,et al.,2021.Frequent genetic alterations in immune checkpoint‒related genes in intravascular large B-cell lymphoma. Blood,137(11):1491-1502.

[38]TakahashiH,NishimakiH,NakanishiY,et al.,2022.Clinical impact of central nervous system-directed therapies on intravascular large B-cell lymphoma: a single institution’s experience.EJHaem,3(2):467-470.

[39]TurnerJJ,MortonLM,LinetMS,et al.,2010.InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.Blood,116(20):e90-e98.

[40]VásquezJ,RomeroV,VilasP,et al.,2019.Progressive edemas and generalized telangiectasia: a presentation of intravascular B-cell lymphoma.Clin Case Rep,7(12):2429-2432.

[41]VieitesB,FragaM,López-PresasE,et al.,2005.Detection of t(14;18) translocation in a case of intravascular large B-cell lymphoma: a germinal centre cell origin in a subset of these lymphomas?Histopathology,46(4):466-468.

[42]Xu-MonetteZY,TuMF,JabbarKJ,et al.,2015.Clinical and biological significance ofde novo CD5⁺ diffuse large B-cell lymphoma in Western countries.Oncotarget,6(8):5615-5633.

[43]YegappanS,CouplandR,ArberDA,et al.,2001.Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.Mod Pathol,14(11):1147-1156.

[44]YuanYY,WangEH,WangL,2022.The first case of a collision tumor of gastrointestinal stromal tumor and intravascular large B cell lymphoma.Ann Hematol,101(1):233-235.

[45]ZhangF,LuoXL,ChenY,et al.,2015.Intravascular large B-cell lymphoma involving gastrointestinal stromal tumor: a case report and literature review.Diagn Pathol,10:214.

[46]ZhangY,ChenC,ZhaoDQ,et al.,2023.P1185: a prospective single-center phase 2 study of zanubrutinib plus R-CHOP in treat-naïve intravascular large B cell lymphoma.HemaSphere, 7(Sl):e1662573.